Basic Information
| LncRNA/CircRNA Name | TMPO-AS1 |
| Synonyms | NA |
| Region | GRCh38_12:98512973-98516422 |
| Ensemble | ENSG00000257167 |
| Refseq | NR_027157 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, ChIP |
| Sample | prostate cancer tissues, cell lines (LNCaP, DU145, 22Rv1, PC-3, WPMY-1) |
| Expression Pattern | up-regulated |
| Function Description | we found that TMPO-AS1 could be a useful diagnostic and prognostic marker for PCa, whose expression was upregulated in PCa samples and associated with poorer prognosis. TMPO-AS1 overexpression increased cell proliferation by promoting cell cycle progression and promoted migration, but reduced apoptosis of PCa cells. in PCa specimens, TMPO-AS1 expression was higher in patients who experienced BCR (biochemical recurrence) compared with patients who did not(P = 0.0031; Table 1). |
| Pubmed ID | 30105831 |
| Year | 2018 |
| Title | Overexpression of AR-regulated lncRNA TMPO-AS1 correlates with tumor progression and poor prognosis in prostate cancer. |
External Links
| Links for TMPO-AS1 | GenBank HGNC NONCODE |
| Links for prostate cancer | OMIM COSMIC |